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 screening in the Netherlands: population based study
Philippe Autier,1,2 Magali Boniol,2 Alice Koechlin,1,2 Cécile Pizot,2 Mathieu Boniol1,2
ABSTRACT
OBJECTIVE
To analyse stage speciic incidence of breast cancer 
in the Netherlands where women have been invited 
to biennial mammography screening since 1989 
(ages 50-69) and 1997 (ages 70-75), and to assess 
changes in breast cancer mortality and quantiied 
overdiagnosis.
DESIGN
Population based study.
SETTING
Mammography screening programme, the 
Netherlands.
PARTICIPANTS
Dutch women of all ages, 1989 to 2012.
MAIN OUTCOME MEASURES
Stage speciic age adjusted incidence of breast cancer 
from 1989 to 2012. The extra numbers of in situ and 
stage 1 breast tumours associated with screening were 
estimated by comparing rates in women aged 50-74 
with those in age groups not invited to screening. 
Overdiagnosis was estimated ater subtraction of the 
lead time cancers. Breast cancer mortality reductions 
during 2010-12 and overdiagnosis during 2009-11 
were computed without (scenario 1) and with (scenario 
2) a cohort efect on mortality secular trends.
RESULTS
The incidence of stage 2-4 breast cancers in women 
aged 50 or more was 168 per 100 000 in 1989 
and 166 per 100 000 in 2012. Screening would be 
associated with a 5% mortality reduction in scenario 
1 and with no influence on mortality in scenario 
2. In both scenarios, improved treatments would 
be associated with 28% reductions in mortality. 
Overdiagnosis has steadily increased over time with 
the extension of screening to women aged 70-75 
and with the introduction of digital mammography. 
Ater deduction of clinical lead time cancers, 32% 
of cancers found in women invited to screening in 
2010-12 and 52% of screen detected cancers would 
be overdiagnosed.
CONCLUSIONS
The Dutch mammography screening programme 
seems to have little impact on the burden of advanced 
breast cancers, which suggests a marginal efect on 
breast cancer mortality. About half of screen detected 
breast cancers would represent overdiagnosis.
Introduction
The primary goal of cancer screening is to decrease cancer 
mortality. Cancer screening afects cancer mortality by 
reducing the number of advanced cancers with poor 
prognosis. In populations where screening is widespread, 
decreases in the incidence of advanced cancer should 
be the irst sign that screening efectively reduces cancer 
mortality.1-4 This indicator has the advantage of being 
independent of treatment. It was recommended for the 
monitoring of the efectiveness of breast screening by the 
International Agency for Research on Cancer handbook 
on breast screening published in 2002 and by proponents 
of mammography screening.5-8
In 1988 a nationwide, population based organised 
cancer screening programme was launched in the 
Netherlands.9 Deaths from breast cancer in Dutch 
women of all ages started to noticeably decrease after 
1995.10 In 2004 the Dutch National Evaluation Team 
reported reductions in the incidence of tumours of 
20 mm or more diameter with positive lymph node 
or distant metastases, or both from 1989 to 1997 
in women aged 50-69.11 However, the incidence of 
smaller tumours with regional or distant metastases 
and tumours of 20 mm or more diameter without 
regional or distant metastases had remained stable.
Using methods similar to those of the Dutch National 
Evaluation Team, we updated the stage speciic 
incidence of breast cancer in the Netherlands until 
2012. From these updates we estimated the numbers 
of deaths from breast cancer that were avoided because 
of screening, and breast cancer overdiagnosis—that is, 
the number of breast cancers that would have never 
been detected during a woman’s lifetime in the absence 
of mammography screening.
Methods
National breast screening programme, 
the Netherlands
From 1989 to 1996, women aged 50-69 were invited 
to attend biennial mammography screening. In 1997 
women aged 70-75 started to be invited. Digital 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Since 1989 in the Netherlands women aged 50-75 have been invited to biennial 
mammography screening; digital mammography was introduced ater 2006
A decrease in incidence of advanced cancers is the irst sign of the efectiveness 
of screening and is independent of the efectiveness of treatments
The last evaluation of the national breast screening programme, published in 
1993, suggested moderate decreases in the incidence of some categories of 
advanced cancer from 1989 to 1997
WHAT THIS STUDY ADDS
From 1989 to 2012, no signiicant decrease in the incidence of stage 2-4 breast 
cancers has been observed in women aged ≥50
Screening would be associated with 0 to 5% reductions in breast cancer 
mortality in women aged ≥50, whereas improved patient management would be 
associated with a 28% reduction
In 2010-12 about one third of breast cancers among women invited to screening 
represented overdiagnosis
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mammography replaced ilm based mammography 
after 2006. Since the inception of the programme 
around 80% of invited women have attended, and 
screening of women aged less than 50 or more than 75 
is uncommon. In 2000, only 2% of Dutch women aged 
45 to 69 used oral combined oestrogen/progestogen 
hormone replacement therapy, decreasing to 0.5% 
or less after 2003,12 a low utilisation rate that had no 
visible impact on the incidence of breast cancer.13
Data sources
We extracted data on breast cancer mortality for 
the Netherlands for 1987 to 2013 (international 
classiication of diseases, 10th revision (ICD-10) code 
C50) from the World Health Organization mortality 
database.14
In January 2015, the Integraal Kankercentrum 
Nederland provided the data on the incidence of in 
situ and invasive breast cancer by size, stage, and 
ive year age group from 1989 to 2012 (data for all 
the Netherlands before 1989 are not available). The 
threshold diameter size for distinguishing cancer 
stage 1 and 2 is 20 mm.15 16 We therefore considered 
in situ and stage 1 cancers as early cancers and stage 
2-4 cancers as advanced cancers. This delineation 
between early and advanced breast cancers is common 
and was used in mammography screening trials 
(for example5). Moreover, even in the era of eicient 
adjuvant treatements, the survival of women with 
stage 1 breast cancer is close to that of women without 
breast cancer, whereas the transition to stage 2 cancer 
is associated with lower survival.17 We obtained data 
on age groups invited to screening by period, the type 
of mammography materials, and numbers of screen 
detected breast cancers in the reports of the Dutch 
National Evaluation Team.18 19
Trend analyses
Using the European Standard Population we age 
standardised the crude incidence and mortality rates.20 
We computed incidence trends of all breast cancers and 
advanced breast cancers for women of all ages, women 
aged less than 50, and women aged 50 or more. We did 
not split trends of stage 2-4 cancers by narrower age 
groups because screen detected cancers among women 
invited to screening could afect the rate of stage 2-4 
cancers in older women not invited to screening. For 
estimating the inluence of screening on the incidence 
of early cancers, we computed incidence rates for in 
situ and stage 1 cancers for age groups invited and not 
invited to screening—that is, women aged less than 50 
(not invited), 50-69 (invited since 1989), 70-74 (invited 
since 1997), and 75 or more (not invited).
For quantifying changes in breast cancer incidence 
and mortality over time, we computed an overall 
percentage change using the annual percentage 
change derived from a linear regression of the log 
transformed age adjusted rates. Analysis of changes 
in temporal trends was done by joinpoint regression.21 
The joinpoint regression identiies periods when 
distinct linear or log linear trends are separated by 
inlexion points (joinpoints). Joinpoint regression was 
performed on data from the earliest available data until 
the last year of available data. A log linear regression 
was used with a maximum of three joinpoints. A 
minimum of three observations was allowed between 
two joinpoints and a minimum of three observations 
was allowed at the beginning and end of the trends.
Breast cancer deaths prevented by screening
Two complementary works have shown that the 
screen detection at stage 1 of three breast cancers 
that would have been diagnosed at stage 2-4 in the 
absence of screening would prevent two deaths from 
breast cancer.22 Firstly, the eight randomised trials on 
breast screening documented that the reduction in 
risk of death from breast cancer is tightly correlated 
with reductions in the risk of having a diagnosis of 
an advanced cancer.23 In these trials, for an average 
participation to the irst screening round of 80%, the 
cumulative incidence of stage 2-4 cancers was on 
average 15% lower in the screening group than in the 
control group.23 Secondly, on the basis of the SEER 
survival data for breast cancer, one study estimated 
that a 15% reduction in stage 2-4 cancers is associated 
with a 10% reduction (95% conidence interval 9% 
to 11%) in breast cancer mortality, and this relative 
reduction is independent of treatment eicacy.22 We 
have used this 15% to 10% (i.e, 3:2 ratio) relation 
between the numbers of advanced cancers and breast 
cancer deaths for estimating mortality reductions 
associated with screening. So, for three fewer stage 
2-4 cancers, there would be two fewer breast cancer 
deaths, and reciprocally. We were therefore willing to 
estimate the diference between the observed rates of 
stage 2-4 breast cancers and the rate that would have 
existed in the absence of screening.
The incidence of advanced breast cancer in the 
Netherlands before screening started is unknown 
because national data on cancer incidence before 1989 
are not available. Because of the close relation between 
the risk of cancer death and the risk of advanced 
cancer when no eicient treatment exists, and because 
eicient adjuvant, chemotherapeutic, and radiotherapy 
treatments were uncommon before 1990,24 we opted for 
an indirect approach by considering that breast cancer 
mortality trends in the 1970s and 1980s paralleled 
trends of advanced breast cancers. Because the analyses 
showed that mortality started to drop in 1995, we 
made a linear projection of mortality to 2012 using the 
annual percentage change prevailing before 1994 (ig 
1) and considered that the diference between mortality 
in 1989 and mortality extrapolated to 2012 was part 
of mortality reductions due to screening. We then 
considered the diference in stage 2-4 cancer rates from 
1989 to 2012 (ig 1) that we also attributed to screening. 
The corresponding reduction in breast cancer mortality 
was derived by multiplying the reduction in stage 2-4 
cancers by 2/3 as explained above (ig 1).
The projection to 2012 assumed that the ascending 
linear trend would persist over time. For testing 
whether the linearity assumption was valid, we 
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itted age-period-cohort models to mortality data of 
women until the inlexion of 1995 (see supplementary 
materials).
Estimation of overdiagnosis
We considered all years, from 1989 to 2012, during 
which there was screening. We deined overdiagnosis 
in women aged 50 to 74 as the incidence of in situ 
and stage 1 breast cancer in excess to the incidence 
that would be expected in the absence of screening, 
corrected for the clinical lead time. In the absence of 
national incidence igures before 1989, we elected to 
take breast cancer incidence trends in women aged 
less than 50 as the trends that should be expected in 
the absence of screening. We also made estimations 
using rates in women aged 75 or more and 75 to 84.
Like the Dutch National Evaluation Team,11 we 
took the age adjusted incidence rates observed in 
1989 as the starting point for computing the expected 
incidence rates in the absence of screening. We applied 
the annual percentage change computed for the three 
age groups not invited to screening to the incidence 
rates of women aged 50 to 69 for 1989-97, and to the 
incidence rates of women aged 50 to 74 for 1998-2012.
We computed the proportions of extra cancers 
diagnosed among women invited to screening for three 
periods: 1989-2012, when women aged 50-69 were 
invited to screening, 1998-2012 when women aged 
70-75 were also invited, and 2007-12 when digital 
mammography replaced ilm based mammography.
The extra cancers included screen detected cancers 
that would have been diagnosed at stage 2-4 in the 
absence of screening. Hence, the stage 2-4 cancers 
that were detected when in situ or at stage 1 (ie, the 
clinical lead time) need to be deduced from estimation 
of overdiagnosis.25 We computed the number of 
advanced cancers that was detected at an earlier 
stage as the mortality reduction due to screening in all 
women aged 50 or more multiplied by 3/2.
Other extra cancers in women aged 50-74 are 
the in situ and stage 1 cancers that could have been 
symptomatic after age 74 or more (when women are 
no longer invited to screening) but that were screen 
detected before age 75. These extra cancers should 
not be considered as overdiagnoses. If these cancers 
were detected in women invited to screening, however, 
their detection should be followed by a compensatory 
drop of in situ and stage 1 cancers in older women not 
invited to screening. We assessed the possibility of a 
compensatory drop by running a joinpoint regression 
on in situ and stage 1 cancers diagnosed after age 74.
Breast cancer mortality reduction in 2010-12 and 
overdiagnosis in 2009-11
To assess the balance between breast cancer 
deaths averted owing to screening and the extent of 
overdiagnosis, we estimated the reductions in the 
numbers of breast cancer deaths in 2010-12 that 
resulted from screening or more eicient treatments. A 
irst scenario did not consider cohort efects on mortality 
and a second scenario considered cohort efects. 
Overdiagnosis was computed in 2009-11 because the 
number of screen-detected cancers in 2012 was not yet 
available.19
Results
Breast cancer mortality
The age adjusted breast cancer mortality of 39.0 per 
100 000 women of all ages in 1987-89 decreased to 
25.8 per 100 000 in 2011-13, hence a 38.1% mortality 
reduction from 1989 to 2013. The reductions over 24 
years were 45.2% in women aged less than 50, 39.1% 
in women aged 50-69, and 33.3% in women aged 70 
or more.
The trends that prevailed before the downward 
inlexions observed in the 1990s were not uniform 
across age groups (ig 2): in women aged less than 
50, a moderate downward trend was already present 
from 1970 onwards, whereas rates in women aged 
50 to 69 remained stable until 1994. In women aged 
70 or more, trends increased until 1997. In women 
aged 50 or more, after a period of relatively stable 
incidence (average percentage change 0.09%, 95% 
conidence interval −0.02% to 0.21%) from 1967 to 
1995, a decline of −2.25% per year (95% conidence 
interval −2.46% to −2.04%) was observed after 1995. 
The further decrease of −2.76% (ie, −3.38% minus 
−0.62%) per year observed in women aged less than 50 
after 1998 is of greater magnitude than the decrease 
observed after 1995 in women aged 50 or more.
The age group contrasts in trends denotes gradual 
decreases in the lifetime risk of breast cancer death 
in successive generations—that is, a cohort efect—
interrupted by noticeable downward inlexions 
occurring across all age groups in 1993 to 1996. 
Supplementary igures S1 to S3 in the supplementary 
materials display the results of the age-period-cohort 
modelling. A forecast of mortality trends in women 
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Fig 1 | Estimations of changes in breast cancer mortality 
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mammography screening. Age adjusted rates are per 
100 000 women aged 50 or more. The black dashed lines 
correspond to trends in the absence of change in rates 
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aged 50 or more based on the age-period-cohort model 
indicates a smooth, progressive tendency towards 
lower mortality after 1994 owing to a steadily lower risk 
of breast cancer death among successive generations of 
women born after 1923 (see supplementary igure S3). 
This steadily lower risk would be associated with long 
term changes in genetic, environmental, and lifestyle 
risk factors associated with breast cancer death. The 
reduction of mortality due to cohort efects would have 
happened independently of screening or of improved 
treatments. This reduction would have ended up as a 
mortality about 5% lower in 2012 than in 1995.
Stage speciic breast cancer incidence
From 1989 to 2012, a total of 27 909 in situ and 
267 989 invasive breast cancers were diagnosed 
among Dutch women of all ages. Trends from 1989 to 
2012 show considerable increases in the incidence of 
in situ tumours and stage 1 cancers, whereas trends 
in stage 2-4 cancers have remained relatively stable 
(see supplementary igure S4). The adoption of the 
axillary sentinel node biopsy procedure by all medical 
institutions in 2002 induced a stage migration that 
led to the upstaging of a sizeable fraction of stage 2 
cancers into stage 3 cancers. This phenomenon is not 
perceptible for stage 1 cancers. A joinpoint analysis of 
stage 1 cancer rates in women of all ages showed annual 
percentage changes of 11.57% (95% conidence 
interval 8.96% to 14.23%) in 1989-93, 1.36% (0.85% 
to 1.87%) in 1993-2005, and 3.48% (2.45% to 4.52%) 
in 2005-12. There is thus no evidence for a downward 
inlexion in stage 1 cancer rates in years during which 
the sentinel node biopsy procedure was generalised.
In women aged 50 or more, the incidence of stage 
2-4 cancers remained practically unchanged over time, 
from 168 per 100 000 in 1989 to 166 per 100 000 in 
2012 (ig 3), with a non-signiicant annual percentage 
change of −0.16% (95% conidence interval −0.36% 
to 0.04%, table 1). From 1995 to 2012 the screening 
programme was fully operational nationwide, with 
participation constantly around 80%. During that 18 
year period the incidence of stage 2-3, stage 4, and 
stage 2-4 cancers remained stable (table 1). In contrast, 
the incidence of in situ and stage 1 cancers increased 
sharply. The comparison of incidence between age 
groups shows noticeable diferences in trends over 
time that correlate with invitation to screening and 
the replacement of ilm based mammography with 
digital mammography (igs 4 and 5). In women aged 
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50-69, the steep increases in incidence in 1990-96 
were followed by further increases until 2007, after 
which other steep increases occurred when digital 
mammography was introduced.
After a nine year period of stable incidence in women 
aged 70-74 similar to that in women aged 75 or more, 
invitation to screening in 1998 led to a sudden increase 
in rates followed by further increases until the advent of 
digital mammography, which prompted new noticeable 
rate increases. Overall, during the 23 year period, a 
sixfold increase in the incidence of in situ cancers 
occurred among women aged 50-74. The incidence 
of stage 1 cancers increased by threefold in women 
aged 50-69 and by 3.5-fold in women aged 70-74. 
During the same period, rates in women aged less 
than 50 or more than 75 increased by 2.6-fold for in 
situ cancer and by 1.3-fold for stage 1 cancers. Of note, 
among women aged 75 or more, joinpoint analyses for 
the incidence of in situ and stage 1 cancers combined 
found two successive periods of increasing annual 
percentage changes, 6.4% per year (95% conidence 
interval 1.3% to 11.8% per year) from 1989 to 1993, 
and 0.7% per year (95% conidence interval 0.2% to 
1.1% per year) from 1993 to 2012. Hence, the extra in 
situ and stage 1 cancers diagnosed in women invited to 
screening were not followed by a downward inlexion 
in trends among older women not invited to screening, 
which could suggest the presence of a compensatory 
decrease at any moment between 1989 and 2012.
Among women aged less than 50, the incidence 
in stage 2-4 cancers has remained stable, except 
between 1998 and 2002 when an increase in stage 2 
cancers took place, which was interrupted by a sudden 
decrease corresponding to the adoption of the sentinel 
node biopsy procedure (see supplementary igure S5).
Causes of mortality reductions
In a first scenario, we assumed that in the absence 
of efficient treatment the ascending trend of 0.09% 
per year observed in 1967-95 among women aged 
50 or more would have persisted until 2012 (fig 1). 
Hence the rates would have changed from 110 per 
100 000 women in 1995 to 112 per 100 000 women 
in 2012—that is, by about 2%. We considered that 
screening did prevent this 2% increase. We then 
estimated that screening was responsible for the 
0.16% per year decline in the incidence of stage 
2-4 cancers after 1989, which resulted in a 4% 
reduction in incidence over the 23 year period (fig 
1). This reduction equated to a mortality decrease of 
about 3% (ie, 4%×2/3, fig 1).
These computations are recapitulated in table 2 for 
2010-12, with their translation in numbers of breast 
cancer deaths. In the irst scenario without a cohort 
efect on mortality, screening would be associated with 
a 5% reduction in breast cancer mortality, whereas 
improved treatments would be associated with a 28% 
reduction in breast cancer mortality. Hence screening 
would have contributed to 15% of reductions in breast 
cancer mortality, whereas improved treatments and 
patient management would have contributed to 85% 
of reductions.
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Fig 4 | Trends in age adjusted in situ breast cancer 
incidence in women by age group in the Netherlands, 
1989 to 2012
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Table 1 | Changes in age adjusted breast cancer incidence in women aged 50 or more in the Netherlands
Cancer stage
1989-2012 1995-2012
Rate in 1989 Rate in 2012 Annual % change (95% CI) Annual % change (95% CI)
In situ and invasive cancers 252.15 407.98 1.50 (1.22 to 1.79) 1.27 (1.07 to 1.46)
In situ cancers 11.52 63.24 5.88 (4.78 to 7.00) 4.19 (3.56 to 4.82)
Invasive cancers 240.64 344.74 1.06 (0.81 to 1.32) 0.88 (0.70 to 1.06)
Stage 1 64.02 176.25 3.24 (2.64 to 3.85) 2.44 (2.12 to 2.75)
Stage 2-3 150.08 150.75 −0.08 (−0.29 to 0.14) −0.10 (−0.43 to 0.23)
Stage 4 17.45 15.47 −0.97 (−1.35 to −0.59) −0.39 (−0.95 to 0.16)
Stage 2-4 167.53 166.22 −0.16 (−0.36 to 0.04) −0.13 (−0.44 to (0.19)
Rates are per 100 000 women.
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In a second scenario we considered that mortality 
trends from 1995 to 2012 declined by about 5% 
(ig 1) because of a cohort efect (see supplementary 
materials). Hence the cohort efect would replace 
the putative efect of screening in the irst scenario, 
whereas factors other than screening would still be 
associated with a 28% reduction in breast cancer 
mortality.
Estimation of overdiagnosis
If incidence in women aged less than 50 is taken as 
the comparison group, during 1989 to 2012 around 
50% extra in situ and stage 1 cancers were diagnosed 
among women in age groups invited to screening 
(see supplementary tables S1 and S2). Extra cancers 
amounted to 56% of in situ and stage 1 cancers in 
2007-12, when digital mammography totally replaced 
ilm based mammography. Using women of older age 
groups not invited to screening as reference led to 
slightly higher proportions of extra cancers.
In 2009-11, 27 682 in situ and invasive breast 
cancers were diagnosed among women aged 50 to 
74 in the Netherlands, 16 965 (61.3%) of which were 
screen detected (table 3). Extra in situ and stage 1 
cancers amounted to 9819 cancers, a portion of which 
represented clinical advances in diagnosis, which 
we estimated as the 640 screen prevented deaths 
from breast cancer (table 2) multiplied by 3/2, for 
obtaining an estimate of 960 cancers (table 3). In 
the irst scenario, after deduction of the 960 cancers 
that were detected at an earlier stage we estimated 
that overdiagnosed cancers represented 32% of all 
breast cancers diagnosed among women in age groups 
invited to screening and 52% of screen detected breast 
cancers. Hence, in the era of digital mammography 
and in the best case scenario, there would be 8859 
overdiagnosed cancers for 640 averted breast cancer 
deaths as a result of screening. Thus for one woman who 
would not die from breast cancer because of screening, 
about 14 women would be overdiagnosed with an in 
situ or a stage 1 cancer. In the second scenario, owing 
to cohort efects there would be overdiagnosis without 
earlier detection of cancers that would be stage 2-4 in 
the absence of screening.
Discussion
Our study is based on the analysis of incidence trends 
of advanced cancer, a method previously utilised by 
the Dutch National Evaluation Team for providing 
evidence that screening was involved in reductions in 
breast cancer mortality.11 Our study shows that after 
23 years of screening, the reduction in breast cancer 
mortality in women aged 50 or more associated with 
screening ranges from 0 to 5%. In contrast, factors 
other than screening, presumably improvements in the 
treatment of patients with breast cancer, would have 
led to a 28% reduction in breast cancer mortality. The 
likelihood of the predominant inluence of treatment 
efectiveness on mortality reductions is supported 
by the observation that the timing and magnitude of 
decreases in mortality were similar among women 
aged less than 50 and among women aged 50-69. 
Moreover, the noticeable reduction in breast cancer 
mortality in women aged less than 50 was independent 
of the incidence of stage 2-4 cancers and thus entirely 
resulted from improved treatments.
The computations in table 2 suggesting a 5% 
reduction in mortality associated with screening are 
based on two suppositions in favour of screening: irstly, 
we considered that screening had somehow afected 
trends of stage 2-4 cancers towards lower rates despite 
the absence of a statistically signiicant decrease in 
incidence of these cancers. Secondly, we posited that 
the diference between the mortality rate linearly 
extrapolated to 2012 and the mortality rate observed 
in 1995 (ig 1) was as a result of screening. Objections 
against the latter supposition could be raised because 
the diference in rates between 1995 and 2012 could 
also result from improved treatments. However, 
the age-period-cohort model (see supplementary 
materials) indicates that the linear extrapolation of 
trends prevailing before 1995 is probably not the most 
Table 2 | Change in breast cancer mortality in women aged 50 or more living in the Netherlands in 2010-12, assuming no cohort efect on mortality 
trends
Parameters Estimate Row Comments
No of breast cancer deaths, 2010-12* 8574 (1)
Decrease in breast cancer mortality from 1995 to 2010-12 (%) 31 (2)
Additional breast cancer deaths if trends before 1995 had persisted until 2010-12:
  Increase in breast cancer mortality (%) 2 (3) See ig 1
  Reduction in breast cancer mortality (%) 33 (4) (2)+(3)
  No of fewer breath cancer deaths 4223 (5) [(1)/(1−(4))]−(1)
Mortality changes due to changes in incidence of advanced breast cancers, 1989 to 2012:
  Decrease in incidence of stage 2-4 breast cancers (%) 4 (6) See ig 1
  Decrease in breast cancer mortality due to decreases in stage 2-4 cancers (%) 3 (7) (6)×2/3 (see methods and ig 1)
Reduction in breast cancer mortality as a result of screening (%) 5 (8) (3)+(7)
Reduction in breast cancer mortality owing to factors other than screening (%) 28 (9) (4)−(8)=(2)−(7)
Breast cancer deaths because of screening and other factors:
  No of breast cancer deaths avoided because of screening 640 (10) (5)×(8)/(4)
  No of breast cancer deaths avoided because of factors other than screening 3583 (11) (5)×(9)/(4)
  % of reduction in breast cancer mortality attributable to screening 15 (12) (10)/(5)
  % of reduction in breast cancer mortality attributable to improved treatments and patient management 85 (13) (11)/(5)
*Source: WHO mortality database.
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likely scenario, and that the long lasting cohort efect is 
likely to contribute to declines in mortality.
The Dutch National Evaluation Team acknowledged 
that after 1997 the incidence of advanced breast 
cancer no longer decreased but tended to return to 
prescreening levels.26 No explanation was, however, 
proposed that would not challenge the efectiveness 
of screening. Other studies in the Netherlands have 
documented the poor inluence of screening on the 
incidence of advanced breast cancer, one study in 
women participating in screening in a southern 
province and another in all women aged 70 to 75.27 28
Stage migration as a result of the sentinel node 
biopsy procedure has led to an upstaging in only 
a fraction of patients, mainly from stage 2 to stage 
3 cancers.29-31 Hence stage migration is unlikely to 
explain the quasi-stability of the incidence of stage 2-4 
cancers.32 We found no explanation for the transient 
increase in stage 2 cancers observed among women 
aged less than 50. Probably this phenomenon was due 
to changes in the histological assessment of surgically 
removed materials. No data on stage speciic incidence 
of breast cancer are available before 1989, and thus it is 
impossible to assess whether the continuous decrease 
in mortality that started in 1970 in women aged less 
than 50 was associated with changes in the incidence 
of advanced cancers among young Dutch women.
These observations on the limited ability of 
mammography screening to reduce the incidence of 
advanced cancers are supported by studies on breast 
cancer mortality. Twenty years after the introduction 
of mammography screening in the Dutch city of 
Nijmegen, deaths from breast cancer did not decline 
any earlier than in the Dutch city of Arnhem or in the 
Netherlands generally.33 The healthcare systems and 
the socioeconomic environments in the Netherlands 
and Belgium are comparable. Breast screening in 
Belgium was implemented about 15 years later than 
in the Netherlands, and in 2000-05 participation to 
screening was still around 50% in Belgium, whereas 
in the Netherlands it has remained around 80% since 
1989.34 The age adjusted breast cancer mortality 
of 37.5 per 100 000 in Belgian women of all ages in 
1987-89 decreased to 26.0 per 100 000 in 2011-13, 
hence a 24 year mortality reduction of 34%, which 
is comparable to the 38% reduction observed in the 
Netherlands.
The steep increases of in situ tumours and stage 
1 cancers in women aged 50 to 74 after invitation to 
screening are typical of period efects afecting age 
groups rapidly exposed to a new detection method. 
Because changes in the incidence of advanced 
cancers were marginal, and because no compensatory 
decrease in the incidence of early stage breast cancer 
was observed in women aged 75 or more, most of the 
increases in in situ tumours and stage 1 cancers in 
women aged 50-74 would represent overdiagnosis.
Overdiagnosis has increased over time with the 
extension of screening to women aged 70-75, and 
with the replacement of ilm based mammography 
by digital mammography. In 2009-11, 51% of in situ 
tumours and stage 1 cancers found in women aged 
50-74 and 52% of screen detected cancers would 
represent overdiagnosis.
A recent study of the Dutch National Evaluation 
Team estimated that 22% of cancers found in women 
invited to screening from 1989 to 2009 represented 
overdiagnosis.35 We found that 22% to 24% of breast 
cancers found among women invited to screening 
during 1989-2009 represented overdiagnosis (see 
supplementary table S3).
The overdiagnosis of stage 1 cancers was about two 
times higher in women aged 70-74 than in women 
aged 50-69 (ig 5). This age contrast accords with the 
Table 3 | Estimation of overdiagnosis in women aged 50-74 years in the Netherlands, 2009-11
Parameters Estimate Row Comments
No of breast cancers diagnosed in women aged 50-74 in 2009-11*:
  In situ 4422 (1)
  Stage 1 12 804 (2)
  Stage 2+ 10 270 (3)
  Not staged 186 (4)
  Total 27 682 (5)
No of screen detected breast cancers† 16 965 (6)
% of screen detected breast cancers 61 (7) (6)/(5)
Estimation of overdiagnosed in situ and stage 1 breast cancers:
  No of extra cancers, considering 57% extra cancers 9819 (8) ((1)+(2))×0.59 (extra cancer proportion 
of 59% from supplementary table S2)
  No of screen detected breast cancers representing  
clinical lead time
960 (9) 612 breast cancer deaths avoided 
because of screening (from row 10 of 
table 2 multiplied by 3/2)
  No of overdiagnosed breast cancers 8859 (10) (8)−(9)
  Breast cancers overdiagnosed among women invited to  
screening (%)
32 (11) (10)/(5)
  Breast cancers overdiagnosed among women with screen  
detected breast cancer (%)
52 (12) (10)/(6)
  Overdiagnosed in situ and stage 1 cancer among women  
invited to screening (%)
51 (13) (10)/((1)+(2))
*Source: Integraal Kankercentrum Nederland.
†Source: Dutch National Evaluation Team, 2014.
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50% overdiagnosis rate found in Dutch women aged 
70-75 by another study.27
Observations in the Netherlands are in line with 
other data showing that the replacement of ilm 
based mammography by digital mammography 
has substantially increased the burden of in situ 
breast tumours without decreasing rates of interval 
cancers.36-39 Hence the advent of digital technologies 
has probably worsened the overdiagnosis problem 
without clear evidence for improvements in the ability 
of screening to curb the risk of breast cancer death. 
The gradual increase in overdiagnosis over time is the 
major factor involved in the increasing lifetime risk of 
in situ or invasive breast cancer that shifted from 1 in 
10 Dutch women in 1990 to 1 in 6.6 in 2010.40
Strengths and limitations of this study
Our study has several strengths. Cancer registration 
in the Netherlands is of high quality, and a study 
estimated that the reliability of cause of death statistics 
in the Netherlands was high (>90%) for major causes 
of death such as cancers.41 The 3:2 relation between 
reductions in stage 2-4 breast cancers and death 
from breast cancer we used is derived from results 
of randomised trials, cancer registries, and cause of 
death registries.
Our study has several limitations. We assumed that 
incidence trends would follow trends in age groups not 
invited to screening and that mortality trends would 
follow trends prevailing before the shifts observed 
in the 1990s. Unlike other studies42 we had no 
contemporary comparison population with or without 
low participation to screening. Moreover, nationwide 
data on breast cancer incidence did not exist before 
1989. The choice to use trends in women aged less 
than 50 and older than 74 was probably the most 
acceptable surrogate for trends that would have existed 
in the absence of screening. Our choice is supported 
by several observations: trends in incidence in women 
aged less than 50, 70-74, and 75 or more were similar 
until 1997. From 1975 to 1998 in the Eindhoven area 
(southwest of the Netherlands), the incidence of breast 
cancer among women aged less than 50, 50-69, and 
70 or more increased at about the same pace.43
Our assumption that in the absence of screening and 
efective patient treatment the incidence of stage 2-4 
cancers would have paralleled that of breast cancer 
mortality is justiied by the close relation between the 
risk of death from breast cancer and the risk of having 
a diagnosis of an advanced breast cancer observed in 
randomised trials.23
Conclusion
The data on advanced breast cancer in the Netherlands 
indicate that the Dutch national mammography 
screening programme would have had little inluence 
on the decreases in breast cancer mortality observed 
over the past 24 years. This conclusion accords with 
the mounting evidence that randomised trials have 
overestimated the ability of mammography screening 
to reduce the risk of deaths from breast cancer in the 
entire life period after irst exposure to mammography 
screening.44-46 In contrast, the extent of overdiagnosis 
is continuously increasing with the invitation of older 
women to screening and the adoption of imaging 
technologies able to detect increasingly smaller breast 
tumours, most of which are of unknown clinical 
importance.
We thank Integraal Kankercentrum Nederland for providing data on 
breast cancer incidence by stage (www.cijfersoverkanker.nl).
Contributors: PA coordinated the study and wrote the irst version 
of the manuscript. He is the guarantor. AK, CP, MB, and MD did the 
statistical analyses. All authors have read the inal version of the 
manuscript.
Funding: This work was part of internally supported research projects 
of the International Prevention Research Institute. No external 
funding was received for this project. The International Prevention 
Research Institute had no influence on the methods, data analyses, 
or discussion.
Competing interests: All authors have completed the ICMJE form and 
declare: no support from any organisation for the submitted work; 
no inancial relationships with any organisations that might have an 
interest in the submitted work in the previous three years, no other 
relationships or activities that could appear to have influenced the 
submitted work.
Ethical approval: Not required.
Data sharing: Data on breast cancer incidence by stage can be 
requested from the Integraal Kankercentrum Nederland. Data on 
breast cancer mortality are available from the WHO mortality database 
(www.who.int).
Transparency: The lead author and manuscript’s guarantor (PA) 
airms that this manuscript is an honest, accurate, and transparent 
account of the study being reported; that no important aspects of the 
study have been omitted; and that any discrepancies from the study 
as planned (and, if relevant, registered) have been explained.
This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on diferent 
terms, provided the original work is properly cited and the use is non-
commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
1 Morrison AS. Intermediate determinants of mortality in the evaluation of 
screening. Int J Epidemiol 1991;20:642-50. doi:10.1093/ije/20.3.642
2 World Health Organization. Cancer IAfRo. Cancer: Causes, Occurrence 
and Control. International Agency for Research on Cancer, 1990.
3 Cole P, Morrison AS. Basic issues in population screening for cancer. 
J Natl Cancer Inst 1980;64:1263-72.
4 Greenwald P, Sondik EJ, Young JLJr. Emerging roles for cancer 
registries in cancer control. Yale J Biol Med 1986;59:561-6.
5 Tabár L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast 
cancer ater mass screening with mammography. Randomised trial 
from the Breast Cancer Screening Working Group of the Swedish 
National Board of Health and Welfare. Lancet 1985;1:829-32. 
doi:10.1016/S0140-6736(85)92204-4
6 Smith RA, Dufy SW, Gabe R, Tabar L, Yen AM, Chen TH. The 
randomized trials of breast cancer screening: what have we learned? 
Radiol Clin North Am 2004;42:793-806, v.
7 Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: 
the development of a monitoring and evaluation system. Br J 
Cancer 1989;59:954-8. doi:10.1038/bjc.1989.203
8 IARC. Breast Cancer Screening: IARC Press 2002.
9 Fracheboud J, de Gelder R, Otto SJ, et al. National evaluation of breast 
cancer screening in the Netherlands 1990-2007. The Netherlands: 
National Evaluation Team for Breast Cancer Screening (NETB), 2009.
10 Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality 
trends between 30 European countries: retrospective trend analysis of WHO 
mortality database. BMJ 2010;341:c3620. doi:10.1136/bmj.c3620.
11 Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL, 
de Koning HJ. National Evaluation Team for Breast cancer 
screening (NETB). Decreased rates of advanced breast cancer 
due to mammography screening in The Netherlands. Br J 
Cancer 2004;91:861-7. doi:10.1038/sj.bjc.6602075.
12 Faber A, Bouvy ML, Loskamp L, van de Berg PB, Egberts TC, 
de Jong-van den Berg LT. Dramatic change in prescribing 
of hormone replacement therapy in The Netherlands ater 
publication of the Million Women Study: a follow-up study. 
Br J Clin Pharmacol 2005;60:641-7. doi:10.1111/j.1365-
2125.2005.02502.x.
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
13 Soerjomataram I, Coebergh JW, Louwman MW, Visser O, van 
Leeuwen FE. Does the decrease in hormone replacement 
therapy also afect breast cancer risk in the Netherlands? J Clin 
Oncol 2007;25:5038-9, author reply 5039-40. doi:10.1200/
JCO.2007.13.7281.
14 World Health Organization. Mortality database. WHO, 2013.
15 American Joint Committee on Cancer. AJCC Cancer Staging Manual, 
6th ed. Springer, New York, 2002:171-80.
16 International Union Against Cancer. TNM Classiication of Malignant 
Tumours. 6th ed. Wiley-Liss, 2002.
17 Walters S, Maringe C, Butler J, et al. ICBP Module 1 Working Group. 
Breast cancer survival and stage at diagnosis in Australia, Canada, 
Denmark, Norway, Sweden and the UK, 2000-2007: a population-
based study. Br J Cancer 2013;108:1195-208. doi:10.1038/
bjc.2013.6.
18 (NETB) NETfBcsitN. NETB interim report 2007: Main results breast 
cancer screening programme in the Netherlands. Erasmus MC, 
Rotterdam, and UMC Radboud, 2007.
19 NETB. NETfBcs. National evaluation of breast screening in the 
Netherlands, 1990-2011/12. Rotterdam, Nijmegen, 2014.
20 Waterhouse J, Muir C, Correa P, et al. Cancer incidence in ive 
continents. Vol III. World Health Organization, 1976.
21 Jointpoint regression program [program]. Version 3.4.2. version, 
2009.
22 Birnbaum J, Gadi VK, Markowitz E, Etzioni R. The Efect of Treatment 
Advances on the Mortality Results of Breast Cancer Screening Trials: 
A Microsimulation Model. Ann Intern Med 2016;164:236-43. 
doi:10.7326/M15-0754.
23 Autier P, Héry C, Haukka J, Boniol M, Byrnes G. Advanced breast 
cancer and breast cancer mortality in randomized controlled trials 
on mammography screening. J Clin Oncol 2009;27:5919-23. 
doi:10.1200/JCO.2009.22.7041.
24 Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de 
Koning HJ. Trends in the usage of adjuvant systemic therapy for 
breast cancer in the Netherlands and its efect on mortality. Br J 
Cancer 2004;91:242-7. doi:10.1038/sj.bjc.6601969.
25 Zahl PH, Jørgensen KJ, Gøtzsche PC. Overestimated lead times 
in cancer screening has led to substantial underestimation of 
overdiagnosis. Br J Cancer 2013;109:2014-9. doi:10.1038/
bjc.2013.427.
26 de Gelder R, van As E, Tilanus-Linthorst MM, et al. Breast 
cancer screening: evidence for false reassurance? Int J Cancer 
2008;123:680-6.
27 de Glas NA, de Craen AJ, Bastiaannet E, et al. Efect of implementation 
of the mass breast cancer screening programme in older women in 
the Netherlands: population based study. BMJ 2014;349:g5410. 
doi:10.1136/bmj.g5410.
28 Nederend J, Duijm LE, Voogd AC, Groenewoud JH, Jansen FH, 
Louwman MW. Trends in incidence and detection of advanced breast 
cancer at biennial screening mammography in The Netherlands: 
a population based study. Breast Cancer Res 2012;14:R10. 
doi:10.1186/bcr3091.
29 Maaskant AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Tutein 
Nolthenius-Puylaert MC, Nieuwenhuijzen GA. Stage migration due 
to introduction of the sentinel node procedure: a population-based 
study. Breast Cancer Res Treat 2009;113:173-9. doi:10.1007/
s10549-008-9913-8.
30 Tvedskov TF. Staging of women with breast cancer ater 
introduction of sentinel node guided axillary dissection. Dan Med 
J 2012;59:B4475.
31 Vanderveen KA, Schneider PD, Khatri VP, Goodnight JE, Bold RJ. 
Upstaging and improved survival of early breast cancer patients ater 
implementation of sentinel node biopsy for axillary staging. Ann Surg 
Oncol 2006;13:1450-6. doi:10.1245/s10434-006-9109-6.
32 Narod SA, Iqbal J, Miller AB. Why have breast cancer mortality 
rates declined? J Cancer Policy 2015;5:8-17. doi:10.1016/j.
jcpo.2015.03.002.
33 Broeders MJ, Peer PG, Straatman H, et al. Diverging breast 
cancer mortality rates in relation to screening? A comparison 
of Nijmegen to Arnhem and the Netherlands, 1969-
1997. Int J Cancer 2001;92:303-8. doi:10.1002/1097-
0215(200102)9999:9999<::AID-IJC1186>3.0.CO;2-B
34 Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in 
neighbouring European countries with diferent levels of screening 
but similar access to treatment: trend analysis of WHO mortality 
database. BMJ 2011;343:d4411. doi:10.1136/bmj.d4411.
35 Ripping TM, Verbeek AL, Fracheboud J, de Koning HJ, van 
Ravesteyn NT, Broeders MJ. Overdiagnosis by mammographic 
screening for breast cancer studied in birth cohorts in The 
Netherlands. Int J Cancer 2015;137:921-9. doi:10.1002/
ijc.29452.
36 Nederend J, Duijm LE, Louwman MW, et al. Impact of the transition 
from screen-ilm to digital screening mammography on interval 
cancer characteristics and treatment - a population based study 
from the Netherlands. Eur J Cancer 2014;50:31-9. doi:10.1016/j.
ejca.2013.09.018.
37 Hof SR, Abrahamsen AL, Samset JH, Vigeland E, Klepp O, Hofvind S. 
Breast cancer: missed interval and screening-detected cancer at 
full-ield digital mammography and screen-ilm mammography-- 
results from a retrospective review. Radiology 2012;264:378-86. 
doi:10.1148/radiol.12112074.
38 Sala M, Domingo L, Macià F, Comas M, Burón A, Castells X. Does 
digital mammography suppose an advance in early diagnosis? 
Trends in performance indicators 6 years ater digitalization. Eur 
Radiol 2015;25:850-9. doi:10.1007/s00330-014-3431-3.
39 Hofvind S, Skaane P, Elmore JG, Sebuødegård S, Hof SR, Lee CI. 
Mammographic performance in a population-based screening 
program: before, during, and ater the transition from screen-ilm 
to full-ield digital mammography. Radiology 2014;272:52-62. 
doi:10.1148/radiol.14131502.
40 van der Waal D, Verbeek AL, den Heeten GJ, Ripping TM, Tjan-
Heijnen VC, Broeders MJ. Breast cancer diagnosis and death in the 
Netherlands: a changing burden. Eur J Public Health 2015;25:320-4. 
doi:10.1093/eurpub/cku088.
41 Harteloh P, de Bruin K, Kardaun J. The reliability of cause-of-death 
coding in The Netherlands. Eur J Epidemiol 2010;25:531-8. 
doi:10.1007/s10654-010-9445-5.
42 Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer 
screening in denmark: A cohort study of tumor size and 
overdiagnosis. Ann Intern Med 2017;166:313-23. doi:10.7326/
M16-0270.
43 Louwman WJ, Voogd AC, van Dijck JA, et al. On the rising trends 
of incidence and prognosis for breast cancer patients diagnosed 
1975-2004: a long-term population-based study in southeastern 
Netherlands. Cancer Causes Control 2008;19:97-106. doi:10.1007/
s10552-007-9075-8.
44 Gøtzsche PC, Olsen O. Is screening for breast cancer with 
mammography justiiable? Lancet 2000;355:129-34. doi:10.1016/
S0140-6736(99)06065-1.
45 Autier P, Boniol M, Smans M, Sullivan R, Boyle P. Statistical 
analyses in Swedish randomised trials on mammography 
screening and in other randomised trials on cancer screening: 
a systematic review. J R Soc Med 2015;108:440-50. 
doi:10.1177/0141076815593403.
46 Autier P, Boniol M, Smans M, Sullivan R, Boyle P. Observed and 
Predicted Risk of Breast Cancer Death in Randomized Trials on Breast 
Cancer Screening. PLoS One 2016;11:e0154113. doi:10.1371/
journal.pone.0154113.
Supplementary information: additional tables and 
igures
